Study of pathological complete response rate with neoadjuvant concurrent chemoradiation with paclitaxel in locally advanced breast cancer.

Indian Journal of Cancer
P IyerSelvaluxmy Ganesarajah

Abstract

Neoadjuvant concurrent chemoradiation (CTRT) is not widely practiced in breast cancers. The current study presents our experience with the use of neoadjuvant CTRT in patients with locally advanced breast cancers (LABC) treated at our center. The study included all consecutive female patients with inoperable stage III LABC treated at Cancer Institute (W.I.A), Chennai, India, from December 2015 to September 2016. Data were collected retrospectively from the patients' case records. The impact of neoadjuvant CTRT on the pathological complete response (pCR) and survival was analyzed. Neoadjuvant chemotherapy consisted of 4 cycles of adriamycin and cyclophosphamide given either before or after 4 cycles of paclitaxel. All chemotherapy cycles were given once in 3 weeks. Concurrent radiotherapy was incorporated with 2 cycles of paclitaxel. The study included 100 patients with a median age of 49 years, among whom 9 (9%) had IIIA disease, 73 (73%) IIIB, and 18 (18%) had IIIC disease. The hormone receptor-positive disease was observed in 36 (36%) patients, triple-negative in 24 (24%), and Her2/neu positive disease in 40 (40%) patients. All patients were operable after completing the planned neoadjuvant treatments. Ninety-one out of 100 (91...Continue Reading

References

Mar 30, 1995·International Journal of Radiation Oncology, Biology, Physics·J D CoxT F Pajak
Apr 13, 2000·Annals of Surgical Oncology·K A SkinnerS C Formenti
Mar 1, 2003·Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology·Silvia C FormentiFranco Muggia
Mar 9, 2005·International Journal of Radiation Oncology, Biology, Physics·Johnny KaoRuth Heimann
Feb 24, 2006·The New England Journal of Medicine·Heikki JoensuuUNKNOWN FinHer Study Investigators
Mar 1, 2006·Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology·Valentina GuarneriAna M Gonzalez-Angulo
Jun 8, 2007·The New England Journal of Medicine·Rinaa S PungliaJay R Harris
Sep 18, 2007·International Journal of Radiation Oncology, Biology, Physics·Viswanathan ShantaRamachandran Radhika
Jun 3, 2014·Critical Reviews in Oncology/hematology·Orit Kaidar-PersonUNKNOWN AROME
Sep 9, 2016·South Asian Journal of Cancer·Bharath RangarajanJyoti Bajpai

❮ Previous
Next ❯

Related Concepts

Related Feeds

Breast Cancer Triple-N

Breast cancer cells have receptors for estrogen, progesterone, HER2 receptors (also called ERBB2). Triple-negative breast cancers do not have any of these receptors. Here are the latest discoveries pertaining to triple-negative breast cancers.

Related Papers

Current Treatment Options in Oncology
Bernardo L RapoportCarol A Benn
International Journal of Gynecological Cancer : Official Journal of the International Gynecological Cancer Society
L SelvaggiG Cormio
© 2021 Meta ULC. All rights reserved